Pages that link to "Q43051293"
Jump to navigation
Jump to search
The following pages link to Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. (Q43051293):
Displaying 18 items.
- CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA (Q24678824) (← links)
- Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study (Q28270259) (← links)
- Innovative treatments for pancreatic cancer. (Q34311382) (← links)
- CA 242 is a new tumor marker for pancreatic cancer (Q34360290) (← links)
- Eradication of large colon tumor xenografts by targeted delivery of maytansinoids (Q34389426) (← links)
- Immunotherapy for pancreatic cancer: current concepts (Q34684162) (← links)
- Monoclonal antibody C242-Pseudomonas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice (Q35604941) (← links)
- Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer (Q35976947) (← links)
- Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer (Q36079626) (← links)
- Comparative study of CA242 and CA19-9 in chronic pancreatitis (Q39993160) (← links)
- Circulating blood group related carbohydrate antigens as tumour markers (Q40381069) (← links)
- Overview of clinical trials employing antibody-targeted superantigens (Q40620642) (← links)
- Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma (Q40943607) (← links)
- A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate d (Q41960323) (← links)
- Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma (Q42023730) (← links)
- Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9 (Q42372132) (← links)
- Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study (Q42390240) (← links)
- Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer (Q89263438) (← links)